| Acțiuni restante | 77,187,823 shares |
| Acțiuni Insider | 27.921.493 shares |
| Proprietatea din interior | 36,17 % |
| Total Insiders | 49 |
Scorul de sentimente din interior
Insider Sentiment Score găsește companiile cumpărate de persoane din interior.
Este rezultatul unui model cantitativ sofisticat, multifactorial, care identifică companiile cu cele mai înalte niveluri de acumulare de persoane interne. Modelul de scoring folosește o combinație a numărului net de persoane din interior care cumpără în ultimele 90 de zile, totalul acțiunilor cumpărate ca procent din flota și totalul acțiunilor deținute de insider. Numărul variază de la 0 la 100, numerele mai mari indicând un nivel mai ridicat de acumulare pentru semenii săi, iar 50 fiind media.
Frecvența actualizării: zilnic
Scorul de sentiment al ofițerului
Scorul de sentiment al ofițerilor găsește companii cumpărate de ofițerii corporativi.
Prin definiție, Ofițerii Corporativi sunt Corporate Insiders, dar spre deosebire de unii dintre ceilalți Insiders (10% Acționari și Membri ai Consiliului de Administrație), Ofițerii lucrează zilnic pentru companie și își folosesc banii atunci când tranzacționează . (10% acționari și membri ai consiliului de administrație sunt adesea administratori de fonduri care gestionează banii altor persoane.) Ca atare, tranzacțiile privilegiate efectuate de către ofițeri sunt mult mai semnificative și ar trebui tratate în mod corespunzător.
La fel ca Scorul Sentimentului Insider, Scorul Sentimentului Ofițerului este rezultatul unui model cantitativ sofisticat, multifactorial, care identifică companiile cu cele mai înalte niveluri de acumulare de ofițeri.
Frecvența actualizării: zilnic
Vedeți Top Picks Insiders, care oferă o listă a companiilor cu cel mai mare sentiment din interior.
Valori cheie ale insiderului
Acest card arată modul în care compania se clasifică de-a lungul diferitelor valori interne. Clasamentul percentilei arată cum se compară această companie cu alte companii de pe piețele din SUA. Clasamentele mai înalte indică situații mai bune.
De exemplu, este în general acceptat că cumpărarea din interior este un indicator pozitiv, astfel încât companiile cu mai multe achiziții din interior s-ar clasa mai sus decât companiile cu mai puține achiziții din interior (sau chiar vânzări din interior).
Numărul net de persoane din interior care cumpără (clasament)
2579 out of 10931
Numărul net de persoane din interior care cumpără este numărul total de persoane din interior care cumpără minus numărul total de persoane din interior care au vândut în ultimele 90 de zile. Rangul percentilei este afișat aici (interval de la 0 la 100%).
Procent din flota cumpărată de persoane din interior (clasament)
2568 out of 10786
Procent of Float Bought by Insiders este numărul total de acțiuni cumpărate de insiders minus numărul total de acțiuni vândute de insiders în ultimele 90 de zile, împărțit la flota totală și înmulțit cu 100.
Graficul privind tranzacțiile privilegiate
Eledon Pharmaceuticals, Inc. tranzacții privilegiate sunt prezentate în graficul următor. Insiders sunt ofițeri, directori sau investitori importanți într-o companie. În general, este în general ilegal ca persoanele din interior să facă tranzacții în companiile lor pe baza unor informații materiale, nepublice. Acest lucru nu înseamnă că este ilegal pentru ei să facă tranzacții în propriile companii. Cu toate acestea, ei trebuie să raporteze toate tranzacțiile către SEC printr-un Formular 4.
Lista de persoane din interior și valori de profitabilitate
Acest tabel prezintă lista persoanelor din interior cunoscute și este generată automat din dosarele dezvăluite SEC. Pe lângă nume, cel mai recent titlu și desemnarea directorului, a ofițerului sau a proprietarului în proporție de 10%, oferim cele mai recente dețineri divulgate. În plus, atunci când este posibil, oferim performanța comercială istorică pentru persoane din interior. Performanța comercială istorică este o medie ponderată a performanței tranzacțiilor reale de cumpărare pe piață deschisă efectuate de către insider. Pentru mai multe informații despre cum se calculează, urmăriți acest webinar YouTube.
See our leaderboard of most profitable insider traders.
| Insider | Profit mediu (%) | Acțiuni Deținut |
Despică Ajustat |
|---|---|---|---|
|
Apple Tree Partners Ii Lp
Director, 10% Owner -
[D]
|
4.218.641 | 4.218.641 | |
|
Apple Tree Partners II - Annex, L.P.
Director, 10% Owner -
[D]
|
3.568.438 | 3.568.438 | |
|
Apple Tree Partners IV, L.P.
Director, 10% Owner -
[D]
|
250.000 | 250.000 | |
| Timothy J Barberich Director - [D] | 121.077 | 121.077 | |
| Biotechnology Value Fund Ii Lp - | 113.152 | 220.460 | |
| Biotechnology Value Fund L P - | 113.152 | 220.460 | |
|
Bvf Gp Holdings Llc
10% Owner -
|
113.152 | 220.460 | |
| Bvf I Gp Llc - | 113.152 | 220.460 | |
| Bvf Ii Gp Llc - | 113.152 | 220.460 | |
|
Bvf Inc/il
10% Owner -
|
113.152 | 220.460 | |
|
Bvf Partners L P/il
10% Owner -
|
220.460 | 220.460 | |
| BVF Partners OS Ltd. - | 113.152 | 220.460 | |
| Biotechnology Value Trading Fund OS LP - | 113.152 | 220.460 | |
| Buckley Stephen Jr. Director - [D] | 11.000 | 11.000 | |
| Erez Chimovits Director - [D] | 3.183.314 | 3.183.314 | |
| Cheryl Cohen Director - [D] | 0 | 0 |
| Insider | Profit mediu (%) | Acțiuni Deținut |
Despică Ajustat |
|---|---|---|---|
| Flesher Gregory J. Chief Executive Officer, Director - [D] [O] | 156.918 | 156.918 | |
| Karen Jean Ferrante | 62.000 | ||
| David-Alexandre C Gros Chief Executive Officer, Director - [D] [O] | 9.000 | 9.000 | |
|
Seth Loring Harrison
Director, 10% Owner -
[D]
|
7.912.079 | 7.912.079 | |
| Jan Hillson Director - [D] | 3.430 | 3.430 | |
| Lee Kalowski Chief Financial Officer - [O] | 40.953 | 40.953 | |
| Keith Katkin Director - [D] | 8.575 | 8.575 | |
| Kessler David A. | 12.000 | ||
| Allan Kirk Director - [D] | 3.430 | 3.430 | |
| Jon Kuwahara See Remarks - [O] | 5.974 | 5.974 | |
|
Mark N Lampert
10% Owner -
|
113.152 | 220.460 | |
|
Lifesci Index Partners Llc
10% Owner -
|
1.065.867 | 1.065.867 | |
| Gary A Lyons Director - [D] | 0 | 0 | |
| June Lee Director - [D] | 3.430 | 3.430 | |
| Paul Sean Little CHIEF FINANCIAL OFFICER - [O] | 10.000 | 10.000 | |
|
Logos Global Management LP
10% Owner -
|
224.071 | 224.071 |
| Insider | Profit mediu (%) | Acțiuni Deținut |
Despică Ajustat |
|---|---|---|---|
| McBride John S. Director - [D] | 3.430 | 3.430 | |
| Jodie Pope Morrison President and CEO, Director - [D] [O] | 57.566 | 57.566 | |
|
Ag Novartis
10% Owner -
|
4.493.458 | 4.493.458 | |
|
Bioventures Ltd Novartis
10% Owner -
|
4.493.458 | 4.493.458 | |
| Christine Ocampo See Remarks - [O] | 23.160 | 23.160 | |
| Walter C Ogier | 20.000 | ||
|
OrbiMed Israel BioFund GP Limited Partnership
Director, 10% Owner -
[D]
|
73.650 | 73.650 | |
|
OrbiMed Israel GP Ltd.
10% Owner -
|
73.650 | 73.650 | |
| Steven Perrin President, Director - [D] [O] | 1.000 | 1.000 | |
| Gerald E Quirk | 62.000 | ||
| Robinson James A. Jr. Director - [D] | 3.430 | 3.430 | |
|
Muneer A Satter
10% Owner -
|
1.771.688 | 1.771.688 | |
| Smith Bryan E. | 120.000 | ||
| Turkel Catherine C. President - [O] | 88.662 | 88.662 | |
|
Martin D Williams
10% Owner -
|
337.700 | 337.700 | |
|
Paul Yook
10% Owner -
|
1.065.867 | 1.065.867 | |
| Yanchik Joseph A., III Director - [D] | 51.092 | 51.092 |
Report errors via our new Insider Auditing Tool
Înregistrări ale achizițiilor interne - Analiza profitului pe termen scurt
În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în ELDN / Eledon Pharmaceuticals, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție și rezultatele sunt teoretice .
Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate reprezintă acțiunile ajustate în funcție de divizarea.
Înregistrări ale vânzărilor din interior - Analiza pierderilor pe termen scurt
În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în ELDN / Eledon Pharmaceuticals, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție și rezultatele sunt teoretice .
Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.
Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate reprezintă acțiunile ajustate în funcție de divizarea.
Istoricul tranzactiilor
Faceți clic pe pictograma link pentru a vedea istoricul complet al tranzacțiilor. Tranzacțiile raportate ca parte a unui plan de tranzacționare automată 10b5-1 vor avea un X în coloana marcată 10b-5.
| Fişier Data |
Comerț Data |
Formă | Insider | Ticker | Titlul de securitate | Cod | Direct | Exercițiu Preț |
Unitate Preț |
Unități Schimbat |
Valoare Schimbat (1K) |
Rămas Opțiuni |
Rămas Acțiuni |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | 2026-01-10 | 4 | Robinson James A. Jr. | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Lee June | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Katkin Keith | ELDN | Common Stock | D | 8.575 | 8.575 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Kirk Allan | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | Hillson Jan | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2026-01-16 | 2026-01-10 | 4 | McBride John S. | ELDN | Common Stock | D | 3.430 | 3.430 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 75.431 | 220.460 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 821.121 | 2.633.679 | ||||||
| 2024-05-13 | 2024-05-09 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1.031.385 | 3.361.803 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 86.341 | 145.029 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 837.146 | 1.812.558 | ||||||
| 2023-05-09 | 2023-05-05 | 4 | BVF PARTNERS L P/IL | ELDN | Common Stock, $0.001 par value | D | 1.055.445 | 2.330.418 | ||||||
| 2022-11-23 | 2022-11-23 | 4 | Perrin Steven | ELDN | Common Stock | D | 2,5969 | 1.000 | 3 | 1.000 | ||||
| 2022-02-02 | 2022-02-01 | 4 | Gros David-Alexandre C | ELDN | Stock Option (right to buy) | D | 3,97 | 108.000 | 108.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Smith Bryan E. | ELDN | Stock Option (right to buy) | D | 3,97 | 120.000 | 120.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Ogier Walter C | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Perrin Steven | ELDN | Stock Option (right to buy) | D | 3,97 | 155.000 | 155.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | McBride John S. | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | LYONS GARY A | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Lee June | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Hillson Jan | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Katkin Keith | ELDN | Stock Option (right to buy) | D | 3,97 | 20.000 | 20.000 | |||||
| 2022-02-02 | 2022-02-01 | 4 | Little Paul Sean | ELDN | Stock Option (right to buy) | D | 3,97 | 155.000 | 155.000 | |||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 975.412 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 1.274.973 | ||||||||
| 2022-01-31 | 3 | LAMPERT MARK N | ELDN | Common Stock, $0.001 par value | D | 58.688 | ||||||||
| 2021-12-21 | 2021-12-20 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 4,4800 | 2.000 | 9 | 9.000 | ||||
| 2021-08-19 | 2021-08-17 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 6,2100 | 4.000 | 25 | 7.000 | ||||
| 2021-06-14 | 2021-06-11 | 4 | Little Paul Sean | ELDN | Common Stock | D | 8,8700 | 10.000 | 89 | 10.000 | ||||
| 2021-06-10 | 2021-06-09 | 4 | Gros David-Alexandre C | ELDN | Common Stock | D | 8,0100 | 3.000 | 24 | 3.000 | ||||
| 2021-05-04 | 2021-05-03 | 4 | Smith Bryan E. | ELDN | Stock Option (Right to Buy) | D | 9,91 | 158.500 | 158.500 | |||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -1.757 | 6.758 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -9.169 | 39.693 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X1 Convertible Preferred Stock | D | -11.776 | 52.145 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -35 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -203 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Series X Convertible Preferred | D | -273 | 0 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 97.615 | 113.152 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 1.944 | 15.537 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 509.410 | 598.624 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 11.278 | 89.214 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 654.215 | 771.780 | ||||||
| 2020-12-28 | 2020-12-22 | 4 | BVF PARTNERS L P/IL | NVUS | Common Stock, $0.001 par value | D | 15.166 | 117.565 | ||||||
| 2020-12-04 | 2020-12-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 21,6000 | -103.200 | -2.229 | 73.650 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,5507 | 9.098 | 232 | 224.071 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,1740 | 15.000 | 393 | 214.973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 27,0200 | -27 | -1 | 199.973 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,8790 | 12.942 | 335 | 200.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,6442 | -12.942 | -345 | 187.058 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 26,4824 | 15.000 | 397 | 200.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 25,9730 | 4.000 | 104 | 185.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24,5299 | 31.000 | 760 | 181.000 | ||||
| 2020-11-06 | 2020-10-30 | 4 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 24,0325 | 5.000 | 120 | 150.000 | ||||
| 2020-11-06 | 3 | Logos Global Management LP See Notes 1 and 2 | NVUS | Common Stock | I | 145.000 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 77.936 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 102.400 | ||||||||
| 2020-10-05 | 3 | LAMPERT MARK N | NVUS | Common Stock | D | 13.595 | ||||||||
| 2020-09-15 | 2020-09-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 500,00 | 1.167 | 1.167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 500,00 | 1.167 | 1.167 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 500,00 | 2.145 | 2.145 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 500,00 | 5.907 | 5.907 | |||||
| 2020-09-15 | 2020-09-11 | 4 | Gros David-Alexandre C | NVUS | Stock Option (Right to Buy) | D | 500,00 | 18.278 | 18.278 | |||||
| 2020-03-20 | 2020-03-19 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0,26 | 50.000 | 50.000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0,26 | 100.000 | 100.000 | |||||
| 2020-03-20 | 2020-03-19 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0,26 | 200.000 | 200.000 | |||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | 0 | ||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | |||||
| 2020-02-25 | 2020-01-14 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 0,2000 | 646.204 | 129 | |||||
| 2019-09-30 | 2019-09-26 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 0,67 | 100.000 | 100.000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 0,67 | 75.000 | 75.000 | |||||
| 2019-09-30 | 2019-09-26 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 0,67 | 60.000 | 60.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Chimovits Erez | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-07-15 | 2019-07-11 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 0,88 | 20.000 | 20.000 | |||||
| 2019-05-22 | 2019-05-21 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1,9114 | -2.937 | -6 | 156.918 | ||||
| 2019-05-22 | 2019-05-20 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 1,9616 | -11.701 | -23 | 159.855 | ||||
| 2019-05-22 | 2019-05-21 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1,9114 | -1.058 | -2 | 5.974 | ||||
| 2019-05-22 | 2019-05-20 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 1,9616 | -4.218 | -8 | 7.032 | ||||
| 2019-05-22 | 2019-05-21 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1,9114 | -1.914 | -4 | 88.662 | ||||
| 2019-05-22 | 2019-05-20 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 1,9616 | -7.623 | -15 | 90.576 | ||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | Chimovits Erez | NVUS | Common Stock | I | 3,1000 | 646.204 | 2.003 | 3.183.314 | ||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Warrants to Purchase Common Stock | I | 646.204 | 646.204 | ||||||
| 2019-05-06 | 2019-05-02 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 3,1000 | 646.204 | 2.003 | 3.183.314 | ||||
| 2019-05-02 | 2019-04-30 | 4 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, par value $0.01 per share | I | 2,7000 | -200 | -1 | 1.065.867 | ||||
| 2019-03-18 | 2019-03-14 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 3,72 | 25.000 | 25.000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 3,72 | 90.000 | 90.000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 25.000 | 171.556 | ||||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 3,72 | 50.000 | 50.000 | |||||
| 2019-03-18 | 2019-03-14 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20.000 | 98.199 | ||||||
| 2018-09-13 | 2018-09-12 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 5,0190 | 16.632 | 83 | 78.199 | ||||
| 2018-09-13 | 2018-09-11 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 4,5560 | 17.048 | 78 | 61.567 | ||||
| 2018-09-07 | 2018-09-05 | 4 | TURKEL CATHERINE C. By Spouse's IRA | NVUS | Common Stock | I | 3,9660 | 805 | 3 | 805 | ||||
| 2018-06-14 | 2018-06-13 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-06-14 | 2018-06-13 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 6,18 | 9.100 | 9.100 | |||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-20 | 3 | LIFESCI INDEX PARTNERS LLC | NVUS | Common Stock, $.001 par value | I | 2.132.134 | ||||||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4,83 | 24.000 | 24.000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 20.000 | 44.519 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 4,83 | 56.500 | 56.500 | |||||
| 2018-03-15 | 2018-03-13 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 30.700 | 146.556 | ||||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 4,83 | 12.000 | 12.000 | |||||
| 2018-03-15 | 2018-03-13 | 4 | Kuwahara Jon | NVUS | Common Stock | D | 11.250 | 11.250 | ||||||
| 2017-11-06 | 2017-11-06 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 4,21 | 50.000 | 50.000 | |||||
| 2017-07-10 | 2017-07-10 | 4 | Kuwahara Jon | NVUS | Stock Option (Right to Buy) | D | 5,61 | 35.000 | 35.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Katkin Keith | NVUS | Stock Option (Right to Buy) | D | 5,85 | 36.000 | 36.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Morrison Jodie Pope | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Cohen Cheryl | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | McBride John S. | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | LYONS GARY A | NVUS | Stock Option (Right to Buy) | D | 5,85 | 18.000 | 18.000 | |||||
| 2017-05-26 | 2017-05-24 | 4 | OCAMPO CHRISTINE | NVUS | Stock Option (Right to Buy) | D | 5,50 | 52.500 | 52.500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | TURKEL CATHERINE C. | NVUS | Stock Option (Right to Buy) | D | 5,50 | 52.500 | 52.500 | |||||
| 2017-05-26 | 2017-05-24 | 4 | FLESHER GREGORY J. | NVUS | Stock Option (Right to Buy) | D | 5,50 | 250.000 | 250.000 | |||||
| 2017-05-11 | 3 | LYONS GARY A | NVUS | No Securities Owned | D | 0 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113.794 | ||||||||
| 2017-05-11 | 3 | FLESHER GREGORY J. | NVUS | Common Stock | D | 113.794 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26.816 | ||||||||
| 2017-05-11 | 3 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 26.816 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24.238 | ||||||||
| 2017-05-11 | 3 | Katkin Keith | NVUS | Common Stock | D | 24.238 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23.160 | ||||||||
| 2017-05-11 | 3 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 23.160 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5.074.220 | ||||||||
| 2017-05-11 | 3 | Chimovits Erez By OrbiMed Israel GP Ltd. | NVUS | Common Stock | I | 5.074.220 | ||||||||
| 2017-05-11 | 2017-05-10 | 4 | FLESHER GREGORY J. | NVUS | Common Stock | D | 9,9900 | 58.959 | 589 | 115.856 | ||||
| 2017-05-11 | 2017-05-10 | 4 | OCAMPO CHRISTINE | NVUS | Common Stock | D | 9,9900 | 10.010 | 100 | 21.590 | ||||
| 2017-05-11 | 2017-05-10 | 4 | TURKEL CATHERINE C. | NVUS | Common Stock | D | 9,9900 | 11.111 | 111 | 24.519 | ||||
| 2017-05-11 | 2017-05-09 | 4 | OrbiMed Israel GP Ltd. See Footnotes | NVUS | Common Stock | I | 2.537.110 | 2.537.110 | ||||||
| 2016-06-16 | 2016-06-15 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-16 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-06-16 | 2016-06-15 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 6,29 | 12.000 | 12.000 | |||||
| 2016-03-15 | 2016-03-15 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 5,7400 | 8.000 | 46 | 11.000 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,37 | -20.000 | 37.878 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -8.015 | 0 | |||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,3700 | 20.000 | 27 | 57.566 | ||||
| 2016-01-08 | 2016-01-08 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 8.015 | 5 | 37.566 | ||||
| 2015-12-17 | 2015-12-15 | 4 | Ferrante Karen Jean | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 9,65 | 189.000 | 189.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-12-17 | 2015-12-15 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 9,65 | 62.000 | 62.000 | |||||
| 2015-11-12 | 2015-11-11 | 4 | Buckley Stephen Jr. | TKAI | Common Stock | D | 11,2500 | 3.000 | 34 | 3.000 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -13.500 | 186.678 | |||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0100 | -13.500 | -189 | 0 | ||||
| 2015-09-22 | 2015-09-21 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 13.500 | 57 | 13.500 | ||||
| 2015-09-08 | 2015-09-08 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13,1300 | -4.668 | -61 | 40.953 | ||||
| 2015-09-04 | 2015-09-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 12,9600 | -2.158 | -28 | 45.621 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,37 | -3.000 | 57.878 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -7.000 | 8.015 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -564 | 312.736 | |||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,3700 | 3.000 | 4 | 29.551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 7.000 | 4 | 26.551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -564 | -8 | 19.551 | ||||
| 2015-07-30 | 2015-07-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 564 | 1 | 20.115 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -12.000 | 313.300 | |||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -12.000 | -164 | 19.551 | ||||
| 2015-07-30 | 2015-07-28 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 12.000 | 19 | 31.551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 0,63 | -7.426 | 15.015 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 2,31 | -2.574 | 0 | |||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 0,6300 | 7.426 | 5 | 19.551 | ||||
| 2015-07-24 | 2015-07-22 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 2,3100 | 2.574 | 6 | 12.125 | ||||
| 2015-07-17 | 2015-07-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2580 | -3.566 | -51 | 4.493.458 | ||||
| 2015-07-15 | 2015-07-14 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,4100 | -27.861 | -401 | 4.497.024 | ||||
| 2015-07-15 | 2015-07-13 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2020 | -20.611 | -293 | 4.524.885 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -8.000 | 325.300 | |||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,7000 | -8.000 | -110 | 9.551 | ||||
| 2015-06-30 | 2015-06-29 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 8.000 | 13 | 17.551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | -8.000 | 333.300 | |||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 13,8300 | -8.000 | -111 | 9.551 | ||||
| 2015-06-30 | 2015-06-26 | 4 | Morrison Jodie Pope | TKAI | Common Stock | D | 1,5800 | 8.000 | 13 | 17.551 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -300 | 200.178 | |||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 14,2000 | -300 | -4 | 0 | ||||
| 2015-06-24 | 2015-06-24 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 300 | 1 | 300 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -6.700 | 200.478 | |||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0000 | -6.700 | -94 | 0 | ||||
| 2015-06-24 | 2015-06-23 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 6.700 | 28 | 6.700 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 4,19 | -2.000 | 207.178 | |||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 14,0200 | -2.000 | -28 | 0 | ||||
| 2015-06-24 | 2015-06-22 | 4 | McBride John S. | TKAI | Common Stock | D | 4,1900 | 2.000 | 8 | 2.000 | ||||
| 2015-06-19 | 2015-06-17 | 4 | BARBERICH TIMOTHY J | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Harrison Seth Loring | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Yanchik Joseph A., III | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-19 | 2015-06-17 | 4 | Kessler David A. | TKAI | Stock Option (right to buy) | D | 14,04 | 12.000 | 12.000 | |||||
| 2015-06-18 | 2015-06-16 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2700 | -1.120 | -16 | 4.545.496 | ||||
| 2015-06-16 | 2015-06-12 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -5.919 | -84 | 4.561.393 | ||||
| 2015-06-16 | 2014-06-15 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -14.777 | -210 | 4.546.616 | ||||
| 2015-06-12 | 2015-06-11 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,2000 | -27.875 | -396 | 4.567.312 | ||||
| 2015-05-28 | 2015-05-26 | 4 | Quirk Gerald E | TKAI | Stock Option (right to buy) | D | 10,81 | 214.605 | 214.605 | |||||
| 2015-04-20 | 2015-04-16 | 4 | Kalowski Lee | TKAI | Common Stock | D | 13,0000 | -4.567 | -59 | 47.779 | ||||
| 2015-04-13 | 3 | Cohen Cheryl | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-04-13 | 2015-04-09 | 4 | Cohen Cheryl | TKAI | Stock Option (right to buy) | D | 11,08 | 25.000 | 25.000 | |||||
| 2015-04-06 | 2015-04-02 | 4 | Kalowski Lee | TKAI | Common Stock | D | 11,4500 | -2.258 | -26 | 52.346 | ||||
| 2015-03-20 | 2015-03-19 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,5000 | -46.141 | -669 | 4.595.187 | ||||
| 2015-03-20 | 2015-03-18 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 14,5000 | -3.000 | -44 | 4.641.328 | ||||
| 2015-01-12 | 3 | Buckley Stephen Jr. | TKAI | No securities are beneficially owned | D | 0 | ||||||||
| 2015-01-12 | 2015-01-08 | 4 | Buckley Stephen Jr. | TKAI | Stock Option (right to buy) | D | 14,49 | 25.000 | 25.000 | |||||
| 2014-10-17 | 2014-10-15 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 13,25 | 134.134 | 134.134 | |||||
| 2014-10-17 | 2014-10-15 | 4 | McBride John S. | TKAI | Stock Option (right to buy) | D | 13,25 | 50.671 | 50.671 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series E Preferred Stock | I | -8.013.003 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-3 Preferred Stock | I | -3.931.085 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-2 Preferred Stock | I | -457.728 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Series D-1 Preferred Stock | I | -4.577.315 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 15,0000 | 150.000 | 2.250 | 1.771.688 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Satter Muneer A See footnote. | TKAI | Common Stock | I | 1.621.688 | 1.621.688 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series E Preferred Stock | I | -24.199.308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-3 Preferred Stock | I | -24.046.035 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-2 Preferred Stock | I | -1.539.643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series D-1 Preferred Stock | I | -8.711.335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series C Preferred Stock | I | -14.604.833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-2 Preferred Stock | I | -644.786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series B-1 Preferred Stock | I | -798.067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Series A Preferred Stock | I | -4.500.000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 15,0000 | 362.500 | 5.438 | 7.912.079 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 7.549.570 | 7.549.579 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series E Preferred Stock | D | -24.199.308 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Series D-3 Preferred Stock | D | -10.675.613 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 15,0000 | 237.500 | 3.562 | 3.568.438 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Apple Tree Partners II - Annex, L.P. | TKAI | Common Stock | D | 3.330.938 | 3.330.938 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Morrison Jodie Pope | TKAI | Stock Option (right to buy) | D | 1,58 | 165.251 | 165.251 | |||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series E Preferred Stock | D | -15.064.469 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-3 Preferred Stock | D | -13.222.826 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-2 Preferred Stock | D | -1.539.643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Series D-1 Preferred Stock | D | -15.396.431 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 15,0000 | 325.000 | 4.875 | 4.644.328 | ||||
| 2014-09-24 | 2014-09-22 | 4 | Novartis Bioventures Ltd | TKAI | Common Stock | D | 4.319.328 | 4.319.328 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series E Preferred Stock | D | -809.955 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Series D-3 Preferred Stock | D | -457.731 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | BARBERICH TIMOTHY J | TKAI | Common Stock | D | 121.077 | 121.077 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-3 Preferred Stock | D | -13.370.422 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-2 Preferred Stock | D | -1.539.643 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series D-1 Preferred Stock | D | -8.711.335 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series C Preferred Stock | D | -14.604.833 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-2 Preferred Stock | D | -644.786 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series B-1 Preferred Stock | D | -798.067 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Series A Preferred Stock | D | -4.500.000 | 0 | ||||||
| 2014-09-24 | 2014-09-22 | 4 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 4.218.632 | 4.218.641 | ||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250.000 | ||||||||
| 2014-09-24 | 3 | Apple Tree Partners IV, L.P. | TKAI | Common Stock | D | 250.000 | ||||||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Stock Option (right to buy) | D | 15,00 | 218.417 | 218.417 | |||||
| 2014-09-18 | 2014-09-17 | 4 | Kalowski Lee | TKAI | Common Stock | D | 54.604 | 54.604 | ||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19.102 | ||||||||
| 2014-09-16 | 3 | Morrison Jodie Pope | TKAI | Common Stock | D | 19.102 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | APPLE TREE PARTNERS II LP | TKAI | Common Stock | D | 18 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51.092 | ||||||||
| 2014-09-16 | 3 | Yanchik Joseph A., III | TKAI | Common Stock | D | 51.092 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337.700 | ||||||||
| 2014-09-16 | 3 | Williams Martin D | TKAI | Common Stock | D | 337.700 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212.712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425.397 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring See footnote. | TKAI | Common Stock | I | 212.712 | ||||||||
| 2014-09-16 | 3 | Harrison Seth Loring | TKAI | Common Stock | D | 425.397 |
